StockNews.AI
EDAP
StockNews.AI
166 days

EDAP to Announce Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025

1. EDAP will announce Q4 and full 2024 results on March 27. 2. A conference call will follow the financial results release. 3. EDAP is a leader in robotic energy-based therapies. 4. Focal One® shows promise in prostate focal therapy and potential expansion. 5. Investor contacts provided for further inquiries.

Earnings
+3.25%Current Return
VS
-1.34%S&P 500
$2.4603/06 07:14 AM EDTEvent Start
$2.5403/07 01:54 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

The announcement of financial results usually encourages investor confidence. Positive outcomes in Q4 could lead to stock price increases, similar to past earnings spikes after favorable reports.

How important is it?

Quarterly earnings are critical for investor evaluations. Anticipation of positive earnings can boost stock prices significantly.

Why Short Term?

Q4 results will have immediate effects post-announcement. Historical precedents suggest immediate stock impacts following quarterly earnings announcements.

Related Companies

ISRGVARNXGN
Company to host conference call and webcast on Thursday, March 27th at 8:30am EDT AUSTIN, Texas, March 6, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024, before the markets open on Thursday, March 27th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date:                Thursday, March 27th Time:                 8:30 am EDT Domestic:        1-800-225-9448 International:    1-203-518-9708 Passcode:        EDAP Webcast:         https://viavid.webcasts.com/starthere.jsp?ei=1706804&tp_key=5b71915afc About EDAP TMS SA A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP TMS introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com. Company ContactBlandine ConfortInvestor Relations / Legal AffairsEDAP TMS SA+33 4 72 15 31 50bconfort@edap-tms.com Investor ContactJohn FrauncesLifeSci Advisors, LLC(917) 355-2395jfraunces@lifesciadvisors.com

Related News